Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apex BiotechnologyTPE:1733 +0.48%80 Return-on-Tangible-Equity is 11.09% as of Dec. 2025, which is 58% above its 10-year median of 7.00. GuruFocus rates TPE:1733 with a GF Score™ of 80/100 and a GF Value™ of NT$30.05 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Apex Biotechnology ranks better than 85.82% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Apex Biotechnology's annualized net income for the quarter that ended in Dec. 2025 was NT$200 Mil. Apex Biotechnology's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$1,806 Mil. Therefore, Apex Biotechnology's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 11.09%.
The historical rank and industry rank for Apex Biotechnology's Return-on-Tangible-Equity or its related term are showing as below:
TPE:1733'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.18 Med: 7 Max: 12.79
Current: 9.17
During the past 13 years, Apex Biotechnology's highest Return-on-Tangible-Equity was 12.79%. The lowest was 0.18%. And the median was 7.00%.
TPE:1733's Return-on-Tangible-Equity is ranked better than 85.82% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs TPE:1733: 9.17
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Apex Biotechnology Return-on-Tangible-Equity Related Terms
Apex Biotechnology Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Apex Biotechnology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.09% mean?
Apex Biotechnology (TPE:1733) has a Return-on-Tangible-Equity of 11.09% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Apex Biotechnology and its competitors. This is 58% above median its historical median of 7.00. Over the past decade, Apex Biotechnology's Return-on-Tangible-Equity has ranged from 0.18 to 12.79. According to the industry distribution chart, Apex Biotechnology ranks #170 out of 1199 companies in the Biotechnology industry, placing it in the top 14.2%.
Is Apex Biotechnology's Return-on-Tangible-Equity too high?
Apex Biotechnology's current Return-on-Tangible-Equity of 11.09% is 58% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 12.79. Based on the distribution chart, Apex Biotechnology ranks #170 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Apex Biotechnology has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #170 out of 1199 companies for Return-on-Tangible-Equity. This places Apex Biotechnology in the top 14% of its industry — outperforming the majority of peers. Historically, Apex Biotechnology's own Return-on-Tangible-Equity has ranged from 0.18 to 12.79 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current Return-on-Tangible-Equity is 11.09%, which is 58% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.05, compared to a current price of NT$31.65 — trading 5.3% above its estimated fair value. The current Return-on-Tangible-Equity is 11.09%, which is 58% above median its 10-year median of 7.00. Apex Biotechnology's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Return-on-Tangible-Equity is 11.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$31.65 is trading 5.3% above its estimated GF Value™ of NT$30.05.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Return-on-Tangible-Equity: 11.09% (58% above median its 10-year median of 7.00)
GF Value™: NT$30.05 vs. price of NT$31.65 (5.3% above fair value)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
80GF Score
Get the complete analysis for TPE:1733
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
